Lys503

Site Information
rISGASEkDIVHSGL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 461125

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:	colorectal cancer ( 1 , 9 , 10 ) , colorectal carcinoma ( 1 , 9 , 10 ) , leukemia ( 6 , 7 , 8 ) , chronic myelogenous leukemia ( 6 , 7 , 8 ) , liver cancer ( 20 , 21 ) , hepatocellular carcinoma ( 20 , 21 ) , liver cancer, surrounding tissue ( 12 , 13 , 14 ) , lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 2 , 15 ) , HCT116 (intestinal) ( 1 , 9 , 10 , 19 ) , HeLa (cervical) ( 3 ) , HepG2 (hepatic) ( 20 , 21 ) , Jurkat (T lymphocyte) ( 4 , 15 ) , K562 (erythroid) ( 6 , 7 , 8 , 18 ) , liver ( 11 , 12 , 13 , 14 ) , MV4-11 (macrophage) ( 15 ) , SW480 (intestinal) ( 1 )

Upstream Regulation
Treatments:	hypoxia ( 1 )

Downstream Regulation
Effects of modification on GLUD1:	protein stabilization ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:	colorectal carcinoma ( 1 )

References
1	Hu K, et al. (2023) Glutamate dehydrogenase1 supports HIF-1α stability to promote colorectal tumorigenesis under hypoxia. EMBO J 42, e112675 37092319 Curated Info
2	Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520 25825284 Curated Info
3	Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51 23954790 Curated Info
4	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
5	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
6	Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Moritz A (2010) CST Curation Set: 9819; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
11	Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4 20167786 Curated Info
12	Tucker M (2010) CST Curation Set: 8954; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989 Curated Info
13	Tucker M (2010) CST Curation Set: 8950; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989 Curated Info
14	Tucker M (2010) CST Curation Set: 8952; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989 Curated Info
15	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
16	Li Y (2008) CST Curation Set: 4757; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989 Curated Info
17	Li Y (2008) CST Curation Set: 4646; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989 Curated Info
18	Moritz A (2006) CST Curation Set: 1968; Year: 2006; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
19	Li Y (2005) CST Curation Set: 967; Year: 2005; Biosample/Treatment: cell line, HCT116/EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
20	Mitchell J (2005) CST Curation Set: 867; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
21	Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info